Mebias Discovery

Executive Summary

Mebias Discovery leverages a proprietary membrane protein-NMR drug discovery platform to identify small molecules that bind to G-protein coupled receptors (GPCRs) while eliminating on-target adverse effects, thereby improving therapeutic index. Founded in 2016 and headquartered in Philadelphia, the company is currently in Phase 1 development, focusing on GPCR targets that have historically been challenging due to toxicity. The platform's ability to select for molecules with reduced side effects could address significant unmet needs in areas such as pain, metabolic disorders, and CNS diseases. While early stage, Mebias' approach has the potential to derisk GPCR drug development and create differentiated therapies. The company remains private and has not disclosed total funding, suggesting it may be operating with limited resources or relying on non-dilutive funding. Successful Phase 1 readouts and strategic partnerships will be critical to advancing its pipeline and validating the platform commercially.

Upcoming Catalysts (preview)

• 2027Phase 1 data readout for lead GPCR program70% success
• Q4 2026Potential pharmaceutical partnership or licensing deal50% success
• 2026Series A financing round to fund pipeline expansion80% success